Nosa Med AB
Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, rest of Europe, the United States, Canada, and internationally. The company offers NOSA allergy filter that filters airborne allergens, such as pollen, pet dander, dust, and mold; NOSA smell training, a smell training medical device to improve the sense of smell for individuals … Read more
Nosa Med AB (NOSA) - Total Liabilities
Latest total liabilities as of September 2025: Skr25.36 Million SEK
Based on the latest financial reports, Nosa Med AB (NOSA) has total liabilities worth Skr25.36 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nosa Med AB - Total Liabilities Trend (2016–2024)
This chart illustrates how Nosa Med AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nosa Med AB Competitors by Total Liabilities
The table below lists competitors of Nosa Med AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Revium Recovery Inc
PINK:RVRC
|
USA | $645.00K |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
India | ₹4.03 Billion |
|
Pacific Orient Bhd
KLSE:6009
|
Malaysia | RM784.00 Million |
|
The Practical Solution Public Company Limited
BK:TPS
|
Thailand | ฿533.28 Million |
|
Advtech
JSE:ADH
|
South Africa | ZAC4.68 Billion |
|
Renova Energia S.A
SA:RNEW11
|
Brazil | R$1.73 Billion |
|
Amata VN PCL
BK:AMATAV
|
Thailand | ฿7.89 Billion |
|
Oncoclinicas do Brasil
SA:ONCO3
|
Brazil | R$7.02 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Nosa Med AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nosa Med AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nosa Med AB (2016–2024)
The table below shows the annual total liabilities of Nosa Med AB from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr4.14 Million | -34.60% |
| 2023-12-31 | Skr6.33 Million | +89.95% |
| 2022-12-31 | Skr3.33 Million | +240.00% |
| 2021-12-31 | Skr980.00K | -93.29% |
| 2020-12-31 | Skr14.61 Million | -7.49% |
| 2019-12-31 | Skr15.79 Million | +11.15% |
| 2018-12-31 | Skr14.21 Million | +89.66% |
| 2017-12-31 | Skr7.49 Million | +108.37% |
| 2016-12-31 | Skr3.60 Million | -- |